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ABSTRACT
Objective: To estimate the total annual cost due to Chronic Hepatitis B
(CHB)-related diseases imposed on each patient and his/her family in
Beijing and Guangzhou, China.
Methods: Economic burden of CHB-related diseases (CHB, compensated
cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma) were
examined. A retrospective cohort of 328 patients in Beijing and 271 in
Guangzhou were identiﬁed to obtain their socioeconomic status, utiliza-
tion and costs of treatment, and work loss days due to illness with a
structured questionnaire. Costs of hospitalization were extracted from
databases of two hospitals in Beijing and Guangzhou Social Insurance
Information System, respectively. The outpatient expenditure per patient
was measured through the rate of outpatient visits and average cost per
visit reported by the patients, while the inpatient cost was calculated
through annual rate of hospitalization and average expenditure for differ-
ent types of hospitals. Self medication and direct nonmedical cost were
also reported. The Human Capital Approach was employed to measure
the work loss cost.
Results: The total annual cost per patient for CHB, compensated cirrho-
sis, decompensated cirrhosis, and hepatocellular carcinoma were
US$1636, US$2722, US$4611, and US$6615 in Beijing, and US$1452,
US$2065, US$4290 and US$6054 in Guangzhou, respectively.
Conclusion: This study conﬁrms that CHB-related diseases impose a sub-
stantial economic burden on patients, families, and the society in China
urban areas. The study demonstrates increasing health-care costs related
to disease progression and provides useful information on cost of treat-
ment and work loss for different disease states, which can be further
utilized in cost-effectiveness evaluation.
Keywords: chronic hepatitis B-related diseases, cost of illness, economic
burden, medical expenditure.
Introduction
Hepatitis B is a major global health concern and the most serious
type of viral hepatitis. Worldwide, an estimated two billion
people have been infected with the hepatitis B virus (HBV),
which was the 10th leading cause of death in the world [1,2].
When a person is infected with HBV for more than 6 months,
it is then classiﬁed as chronic infection. Attacking liver cells,
chronic HBV can lead to cirrhosis, liver cancer, liver failure, and
ultimately, death. Chronic hepatitis B (CHB), affecting approxi-
mately 350 million people worldwide, is responsible for up to 1.2
million deaths worldwide each year [1,3].
Among those chronically infected, 75% cases are found in
Asia. China, as a highly endemic country, bears an estimated 122
million chronic carriers and 30 million CHB patients [4,5], of
which between 15% to 25% will die from complications of
chronic liver diseases such as cirrhosis and liver cancer [3]. In this
article, CHB-related diseases are deﬁned to include CHB, com-
pensated cirrhosis, decompensated cirrhosis, and primary hepa-
tocellular carcinoma (HCC). A study showed that the total
economic loss resulted from CHB-associated diseases could be
probably 58.6 to 107.8 billion RMB (US$8.5 to 15.6 billion) in
year 2001 [6], which laid a heavy burden on the patients and
their families as well as the whole society.
Estimating costs of illness due to CHB is an important public
health issue. However, the exact total economic burden in China
has not been well characterized. Since China is a big country with
uneven socioeconomic development, we intentionally start with
Beijing (the capital of China) and Guangzhou (the capital city of
Guangdong Province, Southeast China), both of which are at the
forefront of China’s economic and social development. Our
study is to measure the average annual cost of CHB and its
complications in Beijing and Guangzhou to illustrate the magni-
tude of the economic burden in the megalopolises of China.
Methodology
After a pilot investigation, considering the geographic location
and socioeconomic condition, one urban community in Beijing
and two urban communities in Guangzhou were typically
sampled as the study sites. Containing all the relative informa-
tion of the residents who have chronic health problems, the
residents’ health records obtained from the information system
of the community health center (CHC) where primary health
care was delivered to the community residents were used to
identify the patients diagnosed with any of the four conditions
(CHB, compensated cirrhosis, decompensated cirrhosis, and
HCC). In each community, all eligible patients were included
and the retrospective cohorts were established to assess the eco-
nomic impacts.
A structured household questionnaire survey was conducted
among the included patients by pretrained professional investi-
gators from CHCs during September 2007. The respondents
were asked to present their disease state and recall the informa-
tion about outpatient services utilization in last three months
(from June to August 2007) and hospitalization in the past year
(from September 2006 to August 2007). The questionnaire was
designed to obtain detailed data including socioeconomic status
(such as gender, age, education, occupation, health insurance),
disease state (illness stages, deﬁnite time and result of diagnosis,
follow-up result, and symptoms), utilization of medical and phar-
maceutical treatment (times of visits, levels of facilities visited,
types of examination, and medications prescribed, length of stay,
surgical procedures and other therapies, and self-medications),
speciﬁc expense on services at a time, other spending relevant to
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the disease (transportation, extra nutrition, etc.) as well as work
loss days (both the patient and the caregivers).
Attributing to the recently updated information systems,
patients on the sampling list could all be located and investigated.
Moreover, since the household surveys were implemented by the
community physicians who have quite a good relationship with
the patients, there was few refusal or nonresponse. However,
those who had not been conﬁrmedly diagnosed so as not to be
enrolled in the databases were excluded from the surveys, as it
might cause selection bias.
To acquire the precise hospital costs, average expenses on
hospitalization for the four CHB-related diseases were extracted
from the database of one tertiary hospital and one secondary
hospital in Beijing according to International Statistical Classiﬁ-
cation of Diseases and Related Health Problems, 10th revision
(ICD-10) code. Comparatively, the average inpatient costs at
different hospital levels were obtained through the Social Insur-
ance Information System in Guangzhou.
The total economic burden of CHB-related disease usually
consists of two parts, direct economic burden, which can be
further divided into direct medical cost and direct nonmedical
cost, and indirect cost in 1-year time span [7]. In this study, all the
cost was respectively calculated for each disease state above.
The direct medical cost, measuring the economic resources
for health-care services utilized, was composed of the average
outpatient expenditure, inpatient expenditure, and cost of medi-
cines self-purchased in retail pharmacies. Annual outpatient or
inpatient expenditure per patient was determined by the visit rate
and the average expense per visit. The formulas were:
1. Direct medical cost = annual outpatient expenditure per
patient + annual inpatient expenditure per patient + annual
expenditure of self-medication per patient.
2. Annual outpatient expenditure per patient = average outpa-
tient expense at a visit ¥ the average rate of outpatient visits
in three months ¥ 4.
3. Annual inpatient expenditure per patient = ∑ (average in-
patient expense at a time at the certain hospital
level ¥ proportion of inpatients at the certain hospital
level) ¥ annual rate of hospitalization per patient.
Cost of transportation and extra health products due to
illness were summed up to acquire direct nonmedical cost. With
the mean of the monthly consumption claimed in the question-
naire, the average yearly amount could be measured.
As for indirect economic burden, the Human Capital
Approach was adopted. The indirect cost of each family
depended on the daily income and days of sick leave of the
patient and the average daily income per caregiver, as well as the
duration of their absence from work for the sake of nursing and
caring.
Results
Features of Study Population
A total of 328 patients in Beijing and 271 in Guangzhou cata-
logued in four disease states were eligible and ﬁnally included in
the cohort. The socioeconomic background of the sample in
Beijing was provided by the display of the patients’ characteris-
tics (Table S1). The proportion of male was higher than that of
female. Generally, average age increased with disease progres-
sion. Among the patients, quite a few (27–46%) stayed retired or
unemployed, whose income was comparatively low. In Guang-
zhou, similar situation was presented. However, much higher
proportion of patients with CHB and compensated cirrhosis had
to pay out-of-pocket in Guangzhou (P < 0.05) (see Table S1 at
Assessment of Total Economic Burden of Chronic Hepatitis B
[CHB]-Related Diseases in Beijing and Guangzhou, China Value
in Health Supporting Information at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_WChen.asp).
Utilization and Cost of Medical and
Pharmaceutical Treatment
Table S2 showed the patients’ utilization of medical treatment in
the two cities. On average, patients went to take outpatient
service once or twice every 3 months and were hospitalized more
frequently with disease progression. Most of the hospitalization
occurred in tertiary hospitals, implying that high cost predomi-
nated in the average expenditure (Table S2 can be found at
Assessment of Total Economic Burden of Chronic Hepatitis B
[CHB]-Related Diseases in Beijing and Guangzhou, China Value
in Health Supporting Information at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_WChen.asp).
It can be observed that average expenditure per outpatient
and inpatient visit generally increased as the disease progressed
except for CHB in Beijing (Table S3). Besides outpatient visits
and hospitalization stay, the patients self-purchased the medi-
cines for different purposes according to physician’s prescription
(Table S3 can be found at Assessment of Total Economic Burden
of Chronic Hepatitis B [CHB]-Related Diseases in Beijing and
Guangzhou, China Value in Health Supporting Information at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_WChen.asp).
It was important to observe any difference in the structure of
direct medical cost between Beijing and Guangzhou (Table S3).
In general, there was no particular trend in the rate of taking
outpatient visit and having inpatient stay. It seemed all patients
except those with HCC in Beijing signiﬁcantly spent much more
for every outpatient visit than their counterparts in Guangzhou.
The average expenditure per hospitalization at different hospital
levels in Guangzhou was, on the contrary, higher than that in
Beijing, except for CHB (Table S3). But since the data were
extracted from the hospital databases or medical insurance
system but with no factual records, the truth remained unknown.
Economic Burden of CHB-Related Diseases
Direct Economic Burden
The direct economic burden was a sum of direct medical and
nonmedical cost, including annual cost of outpatient visits, inpa-
tient visits, and self-medications (Table S4), along with cost of
health products and transportation (Table S5). By calculating,
the direct economic burden for CHB, compensated cirrhosis,
decompensated cirrhosis and HCC were US$1380, US$2282,
US$3870, and US$6084 in Beijing and US$1355, US$1875,
US$3816, and US$5472 in Guangzhou, respectively (see
Tables S4 and S5 at Assessment of Total Economic Burden of
Chronic Hepatitis B [CHB]-Related Diseases in Beijing and
Guangzhou, China Value in Health Supporting Information at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_WChen.asp).
Indirect Economic Burden
The indirect economic burden of CHB-related disease was the
cost estimated from the social perspective. Here the work loss of
both the patient and his/her family members due to the diseases
were taken into consideration. Although it varied in different
disease states and cities, it was too substantial to be overlooked.
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The indirect economic burden for the four diseases concerned
were, sequentially, US$256, US$440, US$741, and US$531 in
Beijing and US$97, US$190, US$474, and US$582 in Guang-
zhou (see Table S6 found at Assessment of Total Economic
Burden of Chronic Hepatitis B [CHB]-Related Diseases in Beijing
and Guangzhou, China Value in Health Supporting Information
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_WChen.asp).
Total Economic Burden
To sum up, the total annual economic burden per patient were
ultimately as follows: US$1636 for CHB, US$2722 for compen-
sated cirrhosis, US$4611 for decompensated cirrhosis, and
US$6615 for HCC in Beijing, while in Guangzhou they were
US$1452, US$2065, US$4290, and US$6054, respectively.
The direct medical cost constituted the majority of the cost,
58% to 83% in Beijing and 70% to 83% in Guangzhou. The
direct nonmedical cost corresponded to 9% to 26% of the total
amount in Beijing and 8% to 20% in Guangzhou, while 8% to
16% of the all-in cost in Beijing as well as 7% to 11% in
Guangzhou were distinguished as indirect economic burden (see
Table S7 found at Assessment of Total Economic Burden of
Chronic Hepatitis B [CHB]-Related Diseases in Beijing and
Guangzhou, China Value in Health Supporting Information at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_WChen.asp).
As for the intensity of the burden, Figure S1 demonstrated the
case brieﬂy. The direct medical cost of the four diseases
accounted for 28% to 208% in Beijing and 37% to 163% in
Guangzhou of the individual income annually. As the gross
domestic product (GDP) per capita of Beijing in 2006 was
US$7314, the economic burden of CHB, the least heavy of the
four, was almost a quarter of the amount, to say nothing of HCC,
whose cost even approached the threshold (see Fig. S1 found at
Assessment of Total Economic Burden of Chronic Hepatitis B
[CHB]-Related Diseases in Beijing and Guangzhou, China Value
in Health Supporting Information at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_WChen.asp).
Discussion
To our knowledge, only few prior studies had attempted to
estimate the cost of CHB-related diseases in China. One study
employed the national health statistics data, but lacked in empiri-
cal evidence of the cost on the individuals [6]. Another study was
initiated to quantify the partial economic impact merely with
data of direct medical cost [8]. Furthermore, this study, along
with the other one published in 2002 [9], only took a sample of
inpatients and outpatients from hospitals, which might overesti-
mate the service utilization. According to the data, the life-long
medial expense for a 30-year-old CHB patient was expected to be
US$21,131 through the Markov model [10].
As some studies on similar topics have been conducted with
claims data from health insurance organizations [6] or patients’
medical records from hospitals [8,9], we mainly employed the
data collected from community ﬁeld surveys. There were at least
two reasons for doing so. First, we acquired the realistic and
detailed information instead of the limited claims numbers to
genuinely detect the resource utilization in management of CHB-
related diseases. Second, records in hospitals could only reveal
the condition of those who “took health care,” but did not
concern patients who were not well treated or who were cared at
community level. Only when the cost could not be accurately
obtained from the survey did we turn to hospitals or health
insurance information system for supports.
Besides the physical and psychological agony of suffering
from the disease, the patient and his/her family also underwent a
signiﬁcant economic pressure. The total annual cost of the
diseases concerned was from the minimum US$1452 to the
maximum US$6615, but the GDP per capita of China was only
US$2331 in 2006. The cost was also massive enough to be
equivalent to a considerable proportion of the household income
in both cities. Especially, with disease progressing, direct cost of
decompensated cirrhosis or HCC exceeded 40% of the dispos-
able household income, which might be regarded as a cata-
strophic expenditure [11,12]. Owing to the large amount of
economic resources consumed, CHB-related diseases did impose
a substantial economic burden on patients, families and the
society in China, at least in the urban areas. The detailed cost
estimates could be further utilized to evaluate the cost-
effectiveness of interventions and support policy decisions on
resource allocation.
For both the rate and cost of hospitalization increased for
patients with more advanced CHB-induced liver diseases, the
entire cost would likely be saved or relieved by effective vacci-
nation or therapies to prevent, delay or reverse the disease
progression. This useful information revealed a necessity for
prevention and early treatment.
Direct nonmedical cost and indirect economic burden due to
sickness were seldom estimated before. In our study, the expenses
on transportation, extra health products were taken into account
and further a considerable proportion of un-conspicuous work
loss cost was also contained. However, only sick leave rather
than job loss or decreased productivity in other forms was
involved, meaning that the actual indirect cost might be higher.
It would be even better to adopt the incidence-based
approach, which estimated the cost of illness from onset to
conclusion for all cases that begin within the period under study,
to ﬁgure out the lifetime costs of the patients. Nevertheless,
limited by the access to information to track the residents’ long-
term use of health services, we could not but exercise the alter-
native, the prevalence-based approach, to measure the cost of
illness in the study period regardless of the date of onset of the
disease. Compared with the lifetime economic burden, these
ﬁgures had their defects, but could still provide such kind of
information on the basis of which economic appraisals for inter-
vention schemes or therapeutic regimens would be developed.
Beijing, the capital of China with a 16 million population, is
the hub of policy and culture in China. Guangzhou, located in
southeast China and with a GDP per capita of US$9145 in 2006,
is the city full of economic vitality. Though there existed slight
differences in utilization and cost of the single service and then
the total costs, the ﬁgures in the two cities could be generalized to
most of the metropolises with great population density, economic
prosperity, and civilized development in China, where patients
can get the best health care but have to bear the heaviest eco-
nomic burden. Eventually, it was worth mentioning that Beijing
and Guangzhou were chosen because of their relatively complete
health information systems that made the patients identiﬁcation
feasible.
Conclusions
This study conﬁrms that CHB-related diseases impose substantial
economic burdens on patients, families, and the society in China
urban areas. The cost would likely be saved or relieved by effec-
tive prevention and early treatment. The study provides useful
information on cost of treatment and work loss for different
disease states and also demonstrates increasing health-care costs
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related to disease progression. These can be further utilized in
cost-effectiveness evaluation of treatment interventions.
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